ASHP Believes New Importation Plan from HHS Unlikely to Provide Cost Savings

Published: August 1, 2019
ASHP Press Release

ASHP believes the Safe Importation Action Plan released yesterday by the Department of Health & Human Services and the Food and Drug Administration (FDA) misses the mark and is unlikely to result in significant cost savings for patients. ASHP objects to any approach to importation that fails to maintain all safety requirements that protect the American drug supply chain.

The Safe Importation Action Plan provides two pathways for importing medications. The first will authorize demonstration projects submitted by pharmacists, wholesalers, or states for importing drugs from Canada. The second pathway will permit manufacturers to import versions of their FDA-approved drugs manufactured abroad.

“Importation jeopardizes patient safety while failing to address the causes of high drug prices,” said Tom Kraus, ASHP Vice President of Government Relations. "We will be watching the development of this plan closely to assess how the FDA is addressing safety concerns. It is unrealistic to believe that this plan will result in significant costs savings.  Policymakers should focus on workable solutions that lower costs, such as increasing generic competition and eliminating costly fees imposed by PBMs.”

About ASHP
ASHP represents pharmacists who serve as patient care providers in acute and ambulatory settings. The organization’s nearly 50,000 members include pharmacists, student pharmacists, and pharmacy technicians. For more than 75 years, ASHP has been at the forefront of efforts to improve medication use and enhance patient safety. For more information about the wide array of ASHP activities and the many ways in which pharmacists advance healthcare, visit ASHP’s website,, or its consumer website,


Posted August 1, 2019

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information